152 related articles for article (PubMed ID: 15339694)
41. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
42. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
43. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.
Helbig G; Hus M; Hałasz M; Dudziński M; Więcławek A; Stachowicz M; Soja A; Kyrcz-Krzemień S
Med Oncol; 2012 Jun; 29(2):1073-6. PubMed ID: 21258876
[TBL] [Abstract][Full Text] [Related]
44. Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission.
Cervetti G; Galimberti S; Carulli G; Petrini M
Leuk Res; 2005 Sep; 29(9):1097-8. PubMed ID: 16038739
[No Abstract] [Full Text] [Related]
45. [Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy].
Mauri M; García M; Reynaga E; Ramila E
Med Clin (Barc); 2007 Jun; 129(4):159. PubMed ID: 17663975
[No Abstract] [Full Text] [Related]
46. [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].
Imagawa J; Harada Y; Yoshida T; Tarutani M; Kimura A; Matsumoto K; Morita K; Harada H
Rinsho Ketsueki; 2011 Jul; 52(7):546-50. PubMed ID: 21821988
[TBL] [Abstract][Full Text] [Related]
47. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
48. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
[TBL] [Abstract][Full Text] [Related]
49. WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
Marton I; Pósfai É; Annus JK; Borbényi Z; Nemes A; Vecsei L; Vörös E
Ideggyogy Sz; 2015 May; 68(5-6):212-6. PubMed ID: 26182612
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A
J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233
[No Abstract] [Full Text] [Related]
51. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody.
Wagner LA; Speckart S; Cutter B; Gleich GJ
J Allergy Clin Immunol; 2009 Jun; 123(6):1407-8. PubMed ID: 19342084
[No Abstract] [Full Text] [Related]
52. [Spontaneous pneumothorax, an unusual manifestation of imatinib-resistant chronic eosinophilic leukemia: an autopsy study].
Fujimi A; Kanisawa Y; Tanaka S; Okuda T; Sato Y; Doi T; Ohta H; Iwasaki S; Ishizu A; Huang Y
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):862-5. PubMed ID: 19432135
[No Abstract] [Full Text] [Related]
53. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
Breccia M; Cilloni D; Cannella L; Stefanizzi C; Tafuri A; Fama A; Santopietro M; Saglio G; Alimena G
Cancer Chemother Pharmacol; 2009 May; 63(6):1161-3. PubMed ID: 18989670
[TBL] [Abstract][Full Text] [Related]
54. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes.
Intermesoli T; Delaini F; Acerboni S; Salmoiraghi S; Spinelli O; Guerini V; Vannucchi AM; Mappa S; Rossi G; Rossi V; Di Bona E; Paratore S; Carobbio A; Rambaldi A; Barbui T; Bassan R
Br J Haematol; 2009 Dec; 147(5):681-5. PubMed ID: 19735261
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
56. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα.
Tsuda K; Tanimoto T; Hayakawa K; Komatsu T
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442
[No Abstract] [Full Text] [Related]
57. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Grignani G; Palmerini E; Stacchiotti S; Boglione A; Ferraresi V; Frustaci S; Comandone A; Casali PG; Ferrari S; Aglietta M
Cancer; 2011 Feb; 117(4):826-31. PubMed ID: 20925044
[TBL] [Abstract][Full Text] [Related]
58. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
59. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
Krauth MT; Binder T; Ohler L; Jäger U; Valent P
Leuk Res; 2008 Nov; 32(11):1779-83. PubMed ID: 18417214
[No Abstract] [Full Text] [Related]
60. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Jain N; Cortes J; Quintás-Cardama A; Manshouri T; Luthra R; Garcia-Manero G; Kantarjian H; Verstovsek S
Leuk Res; 2009 Jun; 33(6):837-9. PubMed ID: 19013640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
